← All trials
NCT04812236
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- May 1, 2023
- First posted
- Mar 23, 2021
- Last posted
- Mar 23, 2021
- Enrollment
- 320
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Pharmaceucal Company LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.